<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923090</url>
  </required_header>
  <id_info>
    <org_study_id>RG_12-098</org_study_id>
    <secondary_id>12/WM/0122</secondary_id>
    <nct_id>NCT01923090</nct_id>
  </id_info>
  <brief_title>Finasteride, Dutasteride and Insulin Action</brief_title>
  <acronym>FIND-IT</acronym>
  <official_title>An Open Label Study of 5α-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if an enzyme in the body (5-alpha reductase, 5αR) is
      important in controlling how the body handles sugar and fat. The investigators believe that
      5αR is a crucial step in regulating these actions as well as controlling how insulin works in
      the body but regulating the amount of steroid hormones including cortisol and testosterone in
      the body. In previous clinical studies, the investigators have shown that the activity of 5αR
      increases as you gain weight and decreases with weight loss. In addition, work that the
      investigators have performed in the laboratory has shown that if you increase 5αR levels in
      liver cell grown in the laboratory, the amount of fat that they contain increases. The
      investigators would therefore like to demonstrate the effect of inhibition 5αR on the
      regulation of insulin, glucose and fat in the body.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>3 weeks</time_frame>
    <description>stable isotope measurements of glucose production rate and glucose disposal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adipose tissue insulin sensitivity</measure>
    <time_frame>3 weeks</time_frame>
    <description>insulin mediated suppression of glycerol release into adipose tissue</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Finasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Finasteride treatment 5mg for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dutasteride treatment 0.5mg for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride</intervention_name>
    <description>Finasteride 5mg once daily for 3 weeks</description>
    <arm_group_label>Finasteride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Dutasteride 0.5mg once daily for 3 weeks</description>
    <arm_group_label>Dutasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex

          -  Age 18-65years

          -  BMI 20-35kg/m2

          -  BMI &gt;35kg/m2

        Exclusion Criteria:

          -  Diabetes Mellitus

          -  Glucocorticoid use within the last 6 months

          -  Uncontrolled hypertension (BP&gt;160/100mmHg)

          -  Drugs know to impact upon glucocorticoid metabolism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy w Tomlinson, MD PhD</last_name>
      <phone>44(0)121 4158715</phone>
      <email>J.W.Tomlinson@bham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jeremy W Tomlinson, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Birmingham</investigator_affiliation>
    <investigator_full_name>Dr Jeremy Tomlinson</investigator_full_name>
    <investigator_title>MRC Senior clinical fellow and Reader in Endocrinology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

